Simple Summary Multiple myeloma (MM) is a frequent hematological malignancy
characterized by the uncontrolled growth of clonal plasma cells, primarily in the bone …

Multiple myeloma is a heterogeneous clonal malignant plasma cell disorder, which remains
incurable despite the therapeutic armamentarium's evolution. Bispecific antibodies (BsAbs) …

Multiple Myeloma (MM) is a malignant growth of clonal plasma cells, typically arising from
asymptomatic precursor conditions, namely monoclonal gammopathy of undetermined …

Drug resistance (DR) of cancer cells leading to relapse is a huge problem nowadays to
achieve long-lasting cures for cancer patients. This also holds true for the incurable …

The administration of blinatumomab was accompanied by several adverse effects, including
activation of regulatory T-cells and cytokine storm. The objective of this study was to produce …

The treatment landscape for multiple myeloma (MM) has evolved significantly over the last
decade with the approval of novel therapies and combinations in the newly diagnosed and …

In the past two decades, immunotherapy has established itself as one of the leading
strategies for cancer treatment, as illustrated by the exponentially growing number of related …

Simple Summary Multiple myeloma is a hematological malignancy arising from the
proliferation of tumor antibody-producing cells in the bone marrow. In this cancer, tumor …

Despite significant progress in managing multiple myeloma (MM) in recent years, certain
patients still have a short duration of therapeutic response, often relapsing within 18 months …

Multiple myeloma (MM) as a haematological malignancy is still incurable. In addition to the
presence of somatic genetic mutations in myeloma patients, the presence of …